RecruitingPhase 3NCT06850454
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy
Sponsor
Mahidol University
Enrollment
140 participants
Start Date
Jan 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
- age of >18 years old
Exclusion Criteria8
- pregnancy or breast feeding
- has emetic episode within 24 hours
- gut obstruction
- uncontrolled brain metastasis
- allergy to or current use of olanzapine
- concomittant moderate or high emetogenic chemotherapy on day 2-5
- Total bilirubin > 2 mg/dl or creatinine clearance < 30 ml/min
- unable to swallow drug
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGolanzapine
olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
DRUGPlacebo
placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06850454
Related Trials
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
NCT074828911 location
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
NCT061207641 location
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
NCT058386382 locations
The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer
NCT075401692 locations
Vomiting Prevention in Children With Cancer
NCT068864511 location